US · AMRX · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Amneal Pharmaceuticals, Inc. (AMRX) intrinsic value and stock valuation
$21.12as of 2026-11-21 · Mkt cap 5.89B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Amneal Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values AMRX with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from AMRX’s statements →
Amneal Pharmaceuticals, Inc. Graham Number
Graham Number: $0.31d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Lantheus Holdings, Inc. (LNTH) $102.10
- Mirum Pharmaceuticals, Inc. (MIRM) $96.13
- Dyne Therapeutics, Inc. (DYN) $15.50
- Indivior Pharmaceuticals Inc (INDV) $36.28
- Envista Holdings Corp (NVST) $22.91
- Telix Pharmaceuticals Limited (TLX) $8.37
- Supernus Pharmaceuticals, Inc. (SUPN) $28.61
- Bausch Health Companies Inc. (BHC) $8.22
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Operating income | $423.1M | $249.3M | $204.4M | -$-94.93M | $152.7M |
| Net income | $72.1M | -$-116.89M | -$-83.99M | -$-129.99M | $10.6M |
| EPSd | $221.9K | -$-378.31K | -$-476.84K | -$-861.2K | $70K |
| Operating cash flow | $340M | $295.1M | $345.6M | $65.1M | $241.8M |
| Capital expenditure | -$-70.06M | -$-74.99M | -$-69.19M | -$-90.59M | -$-47.73M |
| Free cash flow | $269.9M | $220.1M | $276.4M | -$-25.5M | $194.1M |
| Total assets | $3.68B | $3.5B | $3.47B | $3.8B | $3.94B |
| Total debt | $2.74B | $2.59B | $2.75B | $2.85B | $2.88B |
| Net debt | $2.43B | $2.48B | $2.66B | $2.82B | $2.63B |
| Total equity | $5.96M | -$-44.54M | $61.3M | $208.9M | $367M |
| Cash and short-term investments | $310.9M | $112.4M | $93.7M | $27.8M | $247.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Cost of revenue | $1.88B | $1.77B | $1.53B | $1.42B | $1.32B |
| Gross profit | $1.14B | $1.02B | $863.9M | $791.5M | $769M |
| Research and development expenses | $186.2M | $190.7M | $194.8M | $208.7M | $209.6M |
| Selling, general and administrative expenses | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M |
| Other expenses | $0.00 | $104M | $35.1M | $278M | $41.2M |
| Operating expenses | $713M | $771.1M | $659.5M | $886.4M | $616.3M |
| Cost and expenses | $2.6B | $2.54B | $2.19B | $2.31B | $1.94B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $241.1M | $258.6M | $210.6M | $158.4M | $136.3M |
| Depreciation and amortization | $223.6M | $236.2M | $229.4M | $240.2M | $233.4M |
| Ebitda | $603.9M | $439.8M | $500.8M | $440.2M | $401.1M |
| Operating income | $423.1M | $249.3M | $204.4M | -$-94.93M | $152.7M |
| Total other income/expenses, net | -$-283.88M | -$-304.34M | -$-244.64M | -$-153.2M | -$-121.35M |
| Income before tax | $139.2M | -$-55.01M | -$-40.27M | -$-248.13M | $31.4M |
| Income tax expense | $11.3M | $18.9M | $8.45M | $6.66M | $11.2M |
| Net income | $72.1M | -$-116.89M | -$-83.99M | -$-129.99M | $10.6M |
| Weighted average shares outstanding | $313.4M | $309M | $175M | $150.9M | $148.9M |
| Weighted average diluted shares outstanding | $324.8M | $309M | $176.1M | $150.9M | $151.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $310.9M | $112.4M | $93.7M | $27.8M | $247.8M |
| Net receivables | $939.9M | $775.7M | $645.7M | $741.8M | $694.7M |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M |
| Total current assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B |
| Property, plant and equipment, net | $550.3M | $523.7M | $550.1M | $589.4M | $639M |
| Goodwill and intangible assets | $1.16B | $1.33B | $1.49B | $1.69B | $1.76B |
| Long-term investments | $7.82M | $35.9M | $37.1M | $85.6M | $0.00 |
| Total non-current assets | $1.77B | $1.91B | $2.09B | $2.39B | $2.42B |
| Total assets | $3.68B | $3.5B | $3.47B | $3.8B | $3.94B |
| Accounts payable | $254.7M | $259.8M | $143.6M | $166.8M | $131.1M |
| Short-term debt | $21.6M | $340.3M | $227.6M | $104.6M | $46M |
| Deferred revenue | $0.00 | $0.00 | $398.4M | $0.00 | $0.00 |
| Total current liabilities | $881.6M | $1.13B | $846.6M | $752.8M | $677.2M |
| Long-term debt | $2.71B | $2.25B | $2.52B | $2.74B | $2.83B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.79B | $2.42B | $2.56B | $2.84B | $2.9B |
| Capital lease obligations | $102.4M | $107.1M | $110M | $123.5M | $127.4M |
| Total liabilities | $3.67B | $3.55B | $3.41B | $3.59B | $3.57B |
| Common stock | $3.15M | $3.1M | $3.07M | $3.04M | $3.01M |
| Retained earnings | -$-535M | -$-607.06M | -$-490.18M | -$-406.18M | -$-276.2M |
| Accumulated other comprehensive income (loss) | -$-110.73M | -$-65.51M | -$-32.35M | $9.94M | -$-24.83M |
| Total equity | $5.96M | -$-44.54M | $61.3M | $208.9M | $367M |
| Total investments | $7.82M | $37.8M | $39.3M | $87.4M | $0.00 |
| Total debt | $2.74B | $2.59B | $2.75B | $2.85B | $2.88B |
| Net debt | $2.43B | $2.48B | $2.66B | $2.82B | $2.63B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $72.1M | -$-73.88M | -$-48.72M | -$-254.79M | $10.6M |
| Depreciation and amortization | $223.6M | $236.2M | $229.4M | $240.2M | $233.4M |
| Stock-based compensation | $32M | $27.8M | $26.8M | $31.9M | $0.00 |
| Change in working capital | -$-204.52M | -$-4.07M | -$-47.19M | -$-59.95M | -$-133.59M |
| Accounts receivable | -$-120.57M | -$-162.16M | $125.8M | -$-79.07M | -$-16.31M |
| Inventory | -$-87.03M | -$-130.53M | -$-126.18M | -$-102.4M | -$-49.02M |
| Accounts payable | $21.3M | $235.1M | -$-94.45M | $109.6M | -$-43.93M |
| Net cash provided by operating activities | $340M | $295.1M | $345.6M | $65.1M | $241.8M |
| Investments in property, plant and equipment | -$-70.06M | -$-60.34M | -$-46.8M | -$-48.8M | -$-49.43M |
| Acquisitions, net | $0.00 | $12M | $0.00 | -$-84.71M | -$-141.54M |
| Net cash used for investing activities | -$-112.26M | -$-63M | -$-69.19M | -$-174.31M | -$-194.18M |
| Common stock issued | $1.96M | $0.00 | $0.00 | $0.00 | $850K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-31.53M | -$-211.79M | -$-212.57M | -$-106.62M | -$-138.12M |
| Net change in cash | $194.5M | $19.3M | $63.9M | -$-221.51M | -$-90.38M |
| Cash at end of period | $312.9M | $118.4M | $99.1M | $35.2M | $256.7M |
| Operating cash flow | $340M | $295.1M | $345.6M | $65.1M | $241.8M |
| Capital expenditure | -$-70.06M | -$-74.99M | -$-69.19M | -$-90.59M | -$-47.73M |
| Free cash flow | $269.9M | $220.1M | $276.4M | -$-25.5M | $194.1M |
Line items
Line items
Line items
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
- CEO
- Chirag K. Patel
- Employees
- 8.5K
- Beta
- 1.26
Explore
Frequently asked questions
What is the intrinsic value of Amneal Pharmaceuticals, Inc. (AMRX)?
Amneal Pharmaceuticals, Inc. (AMRX) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AMRX undervalued?
AMRX trades at a price of $21.12 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.